卡维地洛与美托洛尔对缺血性心脏病疗效的对比分析(2)
 |
| 第1页 |
参见附件(105KB，1页)。
[3]Pinamonti B，Zech in M，Lenarda A，et al.Persistence of Restrictive left ventricular filling pattern in dilated cardiomyopathy:an ominous prognosis sign [J].J Am Coll Cardiol，1997，29:604-612.
[4]Bristaw MR.Carvedilol treatment of chronic heart failure:a new aera[J].Heart，1998，79:31-34.
[5]Wallhaus TR，Taylor M，De Grado TR，et al.Myocardial free fatty and glucose use agter carvedilol treatment in patients with congrestive heart failure[J].Circulation，2001，103:1441-1446.
[6]Romeo F，Li MD，Shi M，et al.Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells:modulation of Fas/Fsa ligand and caspase pathway[J].Cardiovasc Res,2000，45:788-794.
[7]Billn an GE，Castiillo LC，Hensley, et al.β2-adrenergic receptor antagonists protect against ventricular fibrillation.In vise and vitro evidence for enhanced sensitvity to β2-adrenergic stimulation in animals susceptible for sudden death[J].Cieculation，1997,96:1914-1923.
(收稿日期：2008-01-22)
“本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文”
您现在查看是摘要介绍页，详见PDF附件(105KB，1页)。